Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SHR-A2102 |
| Synonyms | |
| Therapy Description |
SHR-A2102 is an antibody-drug conjugate (ADC) targeting Nectin-4, which potentially inhibits tumor growth (J Clin Oncol 2026 44: 16_Suppl, 4191). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SHR-A2102 | SHRA2102|SHR A2102|Notiretatug Rezetecan | NECTIN4 Antibody 15 | SHR-A2102 is an antibody-drug conjugate (ADC) targeting Nectin-4, which potentially inhibits tumor growth (J Clin Oncol 2026 44: 16_Suppl, 4191). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|